Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib Study of Chidamide in Combination With Celecoxib in Patients With Metastatic Colorectal Cancer Who Had Progression or Were Intolerant of at Least Two Lines of Systemic Therapies (CCmCC)

Next Previous
Trial Profile

A Phase Ib Study of Chidamide in Combination With Celecoxib in Patients With Metastatic Colorectal Cancer Who Had Progression or Were Intolerant of at Least Two Lines of Systemic Therapies (CCmCC)

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 26 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Celecoxib (Primary) ; Tucidinostat (Primary)
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms CCmCC

Most Recent Events

  • 20 Dec 2024 Status changed from recruiting to discontinued.
  • 12 Dec 2023 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
  • 12 Dec 2023 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top